Live tape
Top 8, mentions 7d15,264NVDA4,288 mentions▲ +0.04GOOGL2,537 mentions▲ +0.04AMD1,908 mentions▲ +0.08SPY1,723 mentions▲ +0.06QQQ1,655 mentions▲ +0.05SPCX1,130 mentions▲ +0.06TSLA1,025 mentions▲ +0.05AAPL998 mentions▲ +0.05

Equity · Healthcare

ESPR

NASDAQ

Esperion Therapeutics (ESPR)

3.19 USD +0.16% vs prior close
Esperion Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for ESPR to draw a line in its place.

Track this symbol on TradingView
Market cap
821.2M USD
52-week range
1.11 USD – 4.08 USD
Avg volume
2.0M

as of Jul 10, 2026

Have Esperion Therapeutics (ESPR) insiders bought or sold shares recently?

ESPR has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 13 July 2026.

Form 4

Have Esperion Therapeutics (ESPR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
17 Jun 2026Halladay BenjaminChief Financial OfficerSell10,77334K USD
17 Jun 2026Koenig Sheldon L.President and CEOSell53,588169K USD
17 Jun 2026Looker BenjaminChief Legal OfficerSell11,82437K USD
17 Mar 2026Halladay BenjaminChief Financial OfficerSell6,42417K USD
17 Mar 2026Koenig Sheldon L.President and CEOSell25,57870K USD
17 Mar 2026Looker BenjaminChief Legal OfficerSell5,70815K USD
20 Jan 2026Looker BenjaminGeneral CounselSell1,6895K USD
17 Dec 2025Looker BenjaminGeneral CounselSell6,51724K USD
17 Dec 2025Halladay BenjaminChief Financial OfficerSell7,33727K USD
17 Dec 2025Koenig Sheldon L.President and CEOSell48,244177K USD
17 Oct 2025Looker BenjaminGeneral CounselSell1,2483K USD
Sold11 open-market sales178,930$579K
18 other filings: grants, exercises, tax withholding and transfers, not trades
Have Esperion Therapeutics (ESPR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
13 Jul 2026CARROLL J MARTINDirectorOther177,523
13 Jul 2026Koenig Sheldon L.President and CEOOther2,121,094
13 Jul 2026Halladay BenjaminChief Financial OfficerOther705,410
13 Jul 2026Looker BenjaminChief Legal OfficerOther667,524
13 Jul 2026Harlow John B. Jr.Chief Commercial OfficerOther424,536
13 Jul 2026THOMPSON JOHN CRAIGDirectorOther79,873
13 Jul 2026Fischer Seth H. Z.DirectorOther141,023
13 Jul 2026Shepard JayDirectorOther164,472
13 Jul 2026Hoffman Robert E.DirectorOther85,153
28 May 2026CARROLL J MARTINDirectorAward79,873
28 May 2026Fischer Seth H. Z.DirectorAward79,873
28 May 2026Hoffman Robert E.DirectorAward79,873

Showing the 12 most recent of 18 compensation filings in this window. The figures above count all of them.

Which funds hold Esperion Therapeutics (ESPR)?

8 of the 45 institutional funds we track reported a Esperion Therapeutics position for the quarter ended 30 Jun 2026 — a combined 49.2M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Esperion Therapeutics (ESPR)?
FundPositionSharesValueShares q/q
Two Sigma InvestmentsHeld (±25%)7,126,73922.5M USD−24.7%
Balyasny Asset ManagementNew position4,654,77814.7M USD
Millennium ManagementAdded2,225,7337.0M USD+268.3%
Soros Fund ManagementNew position757,3582.4M USD
Citadel AdvisorsHeld (±25%)461,6491.5M USD−1.3%
GAMCO InvestorsNew position172,500545K USD
Renaissance TechnologiesTrimmed160,200506K USD−90.1%
Marshall WaceTrimmed14,11845K USD−99.8%
AQR Capital ManagementExited
D. E. Shaw & Co.Exited

What has been filed or recorded for Esperion Therapeutics (ESPR)?

The filings we hold for Esperion Therapeutics, newest first: 6 quarterly earnings reports and 2 annual reports, the latest dated 31 Mar 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Esperion Therapeutics (ESPR)?
And
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.10 USDRevenue $80M
31 Dec 2025Annual reportFY 2025 reportedEPS −0.11 USDRevenue $403M
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.16 USDRevenue $87M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.06 USDRevenue $82M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.21 USDRevenue $65M
31 Dec 2024Annual reportFY 2024 reportedEPS −0.28 USDRevenue $332M
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.15 USDRevenue $52M
30 Jun 2024Quarterly earningsQ2 2024 reportedEPS −0.33 USDRevenue $74M

Esperion Therapeutics (ESPR): frequently asked questions

From live data
821.2M

What is Esperion Therapeutics’ market cap?

Esperion Therapeutics is worth 821.2M USD by market value as of 10 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Esperion Therapeutics insiders bought or sold shares recently?

No Esperion Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 13 Jul 2026 (SEC Form 4). See Insiders

8 of 45

Which funds own Esperion Therapeutics?

8 of the 45 funds we track reported a Esperion Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Balyasny Asset Management and Millennium Management. See Funds

−0.10

When did Esperion Therapeutics last report earnings?

Esperion Therapeutics last reported earnings on 31 Mar 2026 for Q1 2026, with EPS of −0.10 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SEC EDGARXBRL company facts
  6. SEC EDGARreported earnings figures and scheduled report dates
  7. SEC EDGARValuation computed from SEC EDGAR filings
  8. Wikipediatext of the lead paragraph, licensed CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) — https://en.wikipedia.org/wiki/Esperion_Therapeutics